Adagene reports higher response rates with increased muzastotug dosing

April 2, 2026 7:00 AM

Adagene Inc. (NASDAQ: ADAG) reported updated data from its Phase 1b/2 study showing muzastotug combined with pembrolizumab achieved a 31 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found